The Sector King: Geron Corp (NASDAQ: GERN)
November 30th, 2009
No comments
GERN is developing bio pharmaceuticals for the treatment of cancer and chronic degenerative diseases including spinal cord injury, heart failure and diabetes. (www.geron.com) Focus: Geron develops a range of anti-cancer therapies, including anti-cancer therapies based on telomerase inhibitors and telomerase therapeutic vaccines, as well as focuses on the development of products using telomerase as a marker for cancer diagnosis, prognosis, patient monitoring, and screening. Read more…
Categories: Independent Equity Research, Stem Cell Technology
Advanced Cell Technology (ACTC.OB or ACT) filed an Investigational New Drug (IND) application on 11/18/09 to conduct a PI/II trial using hESCs to treat a genetic eye disease. 
Updating our Cytori Therapeutics blogs of 11/3/09 and 11/10/09 … 
Athersys (ATHX) is a bio-pharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. ATHX is developing MultiStem, a patented adult-derived “off-the-shelf” stem cell product platform for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. (
